Potent inhibition of thyroid cancer cells by the MEK inhibitor PD0325901 and its potentiation by suppression of the PI3K and NF-kappaB pathways
about
Oxidative stress: a new risk factor for thyroid cancerSelective Targeting of CTNBB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing DrugsBRAF mutations: signaling, epidemiology, and clinical experience in multiple malignancies.Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies.MEK inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivoMolecular pathogenesis and mechanisms of thyroid cancerThe Akt-specific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K/Akt pathway.Standard and emerging therapies for metastatic differentiated thyroid cancer.A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours.Simultaneous suppression of the MAP kinase and NF-κB pathways provides a robust therapeutic potential for thyroid cancerRecent insights into the cell biology of thyroid angiofollicular units.B-Raf mutation and papillary thyroid carcinoma patients.MEK inhibition increases lapatinib sensitivity via modulation of FOXM1Evolving approaches to patients with advanced differentiated thyroid cancerThe role of chemotherapy and latest emerging target therapies in anaplastic thyroid cancer.Overcoming IGF1R/IR resistance through inhibition of MEK signaling in colorectal cancer models.Glycolytic inhibition alters anaplastic thyroid carcinoma tumor metabolism and improves response to conventional chemotherapy and radiation.Dual inhibition of mitogen-activated protein kinase kinase and mammalian target of rapamycin in differentiated and anaplastic thyroid cancer.Enhanced anti-tumour activity of the combination of the novel MEK inhibitor WX-554 and the novel PI3K inhibitor WX-037.Anaplastic thyroid carcinoma: pathogenesis and emerging therapies.Aberrant Signaling through the HER2-ERK1/2 Pathway is Predictive of Reduced Disease-Free and Overall Survival in Early Stage Non-Small Cell Lung Cancer (NSCLC) Patients.Multikinase inhibitors: a new option for the treatment of thyroid cancer.Translational research in endocrine surgery.Spanish consensus for the management of patients with anaplastic cell thyroid carcinoma.Histone deacetylation of NIS promoter underlies BRAF V600E-promoted NIS silencing in thyroid cancer.The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition.BRAF mutation-selective inhibition of thyroid cancer cells by the novel MEK inhibitor RDEA119 and genetic-potentiated synergism with the mTOR inhibitor temsirolimus.Inhibition of nuclear factor-kappa B differentially affects thyroid cancer cell growth, apoptosis, and invasion.Distinct genetic alterations in the mitogen-activated protein kinase pathway dictate sensitivity of thyroid cancer cells to mitogen-activated protein kinase kinase 1/2 inhibition.[Current status of therapeutic approaches with targeted therapies in malignant thyroid cancer. Highlights from the 2011 ASCO Congress].Targeting irradiation-induced mitogen-activated protein kinase activation in vitro and in an ex vivo model for human head and neck cancer.
P2860
Q28388902-956C600C-91AB-4312-BDA4-1B00236385BBQ28547522-4C94ED70-AC20-47BA-942A-74C7E36F388EQ30458424-EF16B32B-A4A6-48D0-BDAF-CBC1683C9554Q33691759-154A93CB-96D6-4822-8AC1-C4299410F98DQ34109756-7ECA8DA9-0EAA-4067-A69D-ACDFFFAED6DEQ34329018-393502A0-C693-410C-9C58-9F5E2D006AEBQ34758583-25CDCBF5-2DB4-4AE1-AF1A-9C650C9D4A70Q35583906-40EAFB49-C4A7-4D0E-9E56-6799C51E8521Q35677661-6F81C7CD-84DE-41B5-B8B7-2A954DD8E5C0Q36012586-E3C92053-29D4-451A-BA1F-91B5AD36D8EFQ36724051-617CD0C5-A7E5-4E50-BE36-202A4C68CA19Q36741221-37049C8E-D9E4-4DCA-AF5A-209D7ADB072BQ36833298-CCD5A2C9-AB82-41C7-A582-4FEB9C28C939Q36864736-FDDAC83C-3A96-4E27-ACD3-4EEFF6AD9BFCQ37209593-C45C264E-8DBE-404C-96B4-924610392ECFQ37349748-93AFEDBD-0CB7-4753-899E-016493B13A81Q37377092-0931F319-8179-4F40-AAFD-1F4718FF2F1CQ37379562-6E26B677-1EE3-4B81-9B48-A64E15520C5AQ37421296-931181A0-C19C-4CEE-93B9-C130956EAB23Q37526750-D8FD68CE-0131-4F48-B121-96FDBA2B1633Q37667783-C83E29AF-D5AD-4EC3-8293-DF7888AD30CFQ37921602-0EB75044-4825-4854-B78E-56C512BCDD08Q38135137-5D9D4513-3F73-4BB7-A588-6FBDEDE637CFQ38798863-A3AE0602-FA0C-428F-8B5A-35E79DC0EBE8Q39062132-D9203F46-0AB9-4819-B9A5-48EF56CBE9A4Q39380338-A0CC82F7-D4DD-437E-80F3-9EC99E9D3EB8Q39586177-6EA87A00-7257-4D6F-BD9A-3005BC9FEC43Q39701467-6D0B045A-039E-4D57-972C-87D67CE3DAA6Q39842295-E2A0C1AC-1080-4898-AA35-BCE3DBE89D4AQ51184181-C8099D30-5BC5-47AA-8750-F72B1412C85CQ53795429-064DA248-FFE0-45C3-98F6-A2608BB245B6
P2860
Potent inhibition of thyroid cancer cells by the MEK inhibitor PD0325901 and its potentiation by suppression of the PI3K and NF-kappaB pathways
description
2008 nî lūn-bûn
@nan
2008 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Potent inhibition of thyroid c ...... he PI3K and NF-kappaB pathways
@ast
Potent inhibition of thyroid c ...... he PI3K and NF-kappaB pathways
@en
type
label
Potent inhibition of thyroid c ...... he PI3K and NF-kappaB pathways
@ast
Potent inhibition of thyroid c ...... he PI3K and NF-kappaB pathways
@en
prefLabel
Potent inhibition of thyroid c ...... he PI3K and NF-kappaB pathways
@ast
Potent inhibition of thyroid c ...... he PI3K and NF-kappaB pathways
@en
P2860
P356
P1433
P1476
Potent inhibition of thyroid c ...... he PI3K and NF-kappaB pathways
@en
P2093
Mingzhao Xing
P2860
P304
P356
10.1089/THY.2007.0357
P50
P577
2008-08-01T00:00:00Z